Status:
WITHDRAWN
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
Lead Sponsor:
Lisata Therapeutics, Inc.
Conditions:
Covid-19
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.
Detailed Description
This open-label clinical trial will explore the safety and potential efficacy of peripheral blood derived autologous CD34+ cells for the repair of COVID-19 induced pulmonary damage in adults. Eligible...
Eligibility Criteria
Inclusion
- Initial diagnosis with COVID-19 based on nasopharyngeal, oropharyngeal, or tracheobronchial aspirate SARS CoV-2 RT-PCR test
- Receiving or received ventilatory support for COVID-19 pneumonia/ARDS
- Evidence for ongoing pulmonary involvement based on P/F ratio \<300
- Able to provide informed consent
Exclusion
- Immunocompromised or current use of immunosuppressive agents other than corticosteroids
- History of autoimmune disease
- Evidence of multiorgan failure
- Subject is pregnant or lactating at the time of signing the consent
- Participation in any other clinical trial of an experimental treatment for COVID-19
- History of sickle cell disease
Key Trial Info
Start Date :
October 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04522817
Start Date
October 5 2020
End Date
May 1 2021
Last Update
October 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health
New York, New York, United States, 10016